VEGFA and colorectal carcinoma: Circulating miR-126 could be a predictive biomarker in metastatic CRC for treatment with the monoclonal anti-VEGF antibody Bevacizumab since [159] poor patient response to Bevacizumab was associated with increased levels of extracellular miR-126 in plasma.